• The pilot phase of a platform that integrates Big Data and AI for clinical decision-making at individual and population level in these patients has been developed

  • It is the first technology of its kind created for a personalized follow-up in long cancer survivors

  • The tool has been identified as an excellent innovation by the Innovation Radar of the European Commission

The first results delivered by the European-funded research project CLARIFY (Cancer Long Survivors Artificial Intelligence Follow Up) were presented to the healthcare authorities of the Madrid Regional Government on May 17th. The project uses Big Data and Artificial Intelligence (AI) to improve the quality of life post treatment of long cancer survivors.

CLARIFY Consortium researchers

CLARIFY researchers have developed the CLARIFY Platform, a tool that allows healthcare professionals to understand, analyze and make decisions based on real data analysis from patients. The goal is to determine a follow-up adapted to the individual needs of each type of patients that allows for improving their health status and optimize their care.

The European Commission´s Innovation Radar, an initiative to identify high potential innovations in R&I projects and their specific needs to “go to market”, has selected the CLARIFY Platform as an excellent innovation and CLARIFY Consortium partners SERMAS, HOLOS and Kronohealth SL as key innovators for the innovative work they are active in delivering.

The pilot version of the CLARIFY Platform was presented by Dr Mariano Provencio, the project´s principal investigator and Chief of Medical Oncology at the Hospital Puerta de Hierro-Majadahonda, at the session How can new technologies improve clinical practice in medical oncology with representatives from the Madrid Regional Government healthcare system and other actors involved in biomedical research.

“This technology integrates and analyzes in real time anonymized data from different sources (clinical and genomic data, biomedical publications, information from wearable devices, quality of life questionnaires, among others) to extract knowledge” explains Prof. Pedro Sousa, CEO of HOLOS and developer of the Platform. It also allows queries about the population or about one single patient for a detailed analysis.


Risk factors that may deteriorate a patient condition after THE end of treatment

Supported by scientific evidence, the clinical decision making process becomes “more intelligent” allowing to obtain profiles and models to stratify patients by risk and personalize their follow-up.

Current follow-up models do not address the physical, functional, and psychosocial needs of long cancer survivors on the mid and long term, which have an important impact on their quality of life. However, as Dr. María Torrente, CLARIFY Coordinator showed in the presentation “with the CLARIFY Platform it is possible to determine the factors that predict poor health status and measure the risk of and relapse in order to personalize pathways for cancer follow-up care”.

For the moment the Platform focuses on three prevalent types of cancer with long-survival rates, i.e. breast, lung and lymphomas, which, given their coexistence and common clinical factors, secondary effects, toxicities, drugs and radiotherapy, the results obtained could then be extrapolated to less prevalent tumours.